The measurement of two biomarkers in women with ovarian masses appears to be accurate in disginguishing which patients are most likely to have cancer.
The measurement of two biomarkers in women with ovarian masses appears to be accurate in distinguishing which patients are most likely to have cancer, allowing those patients to be referred to gynecologic oncologists for further management, according to research findings presented at the 2008 Society of Gynecologic Oncologists' Annual Meeting on Women's Cancer in Tampa, FL.
Richard Moore, MD, of Brown University in Providence, RI, and colleagues measured the blood proteins HE4 and CA125II in nearly 500 women with ovarian masses participating in a clinical trial in order to determine the biomarkers' predictive value in detecting ovarian cancer.
The researchers found that a "high-risk" test result correctly predicted 95% of cases of epithelial ovarian cancer, while a "low-risk" result correctly predicted the absence of cancer in most patients, leading to a negative predictive value of 95%.
More details on this research can be found at http:// http://www.sgo.org/content.aspx?id=58.
A Legacy of Excellence: Reflecting on the Final Print Edition of Contemporary OB/GYN
April 25th 2025Marking the end of an era and the beginning of a new chapter, the final print edition of Contemporary OB/GYN celebrates over 50 years of evidence-based guidance and unwavering support for clinicians.
Read More